The assay demonstrated a significantly higher level of CD63‐positive EVs in BlCa patients compared to BPH (2.3‐fold, p = 0.007) and healthy controls (16‐fold, p = 0.00001) (Figure 2h). This evidence concerns the gene CD63 and bladder transitional cell carcinoma.